Previous clinical studies suggest that the Toll-Like Receptor 9 ( TLR9 ) agonist DIMS0150 not only induces production of key anti-inflammatory cytokines as IL-10 but interestingly also enhances steroid sensitivity in steroid refractory UC patients .